

# SECURITIES AND EXCHANGE COMMISSION

## FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-01-17** | Period of Report: **2013-01-15**  
SEC Accession No. [0001127602-13-002179](#)

([HTML Version](#) on [secdatabase.com](#))

### REPORTING OWNER

#### **CLACKSON TIMOTHY P**

CIK: **1242992**

Type: **4** | Act: **34** | File No.: **000-21696** | Film No.: **13535283**

Mailing Address

C/O ARIAD  
PHARMACEUTICALS INC  
26 LANDSDOWNE STREET  
CAMBRIDGE MA 02139

### ISSUER

#### **ARIAD PHARMACEUTICALS INC**

CIK: **884731** | IRS No.: **223106987** | State of Incorpor.: **DE** | Fiscal Year End: **1231**  
SIC: **2836** Biological products, (no diagnostic substances)

Mailing Address

26 LANDSDOWNE  
CAMBRIDGE MA 02139

Business Address

26 LANDSDOWNE ST  
CAMBRIDGE MA 02139  
6174940400

# FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### OMB APPROVAL

OMB Number: 3235-0287  
Expires: 02/28/2011  
Estimated average burden hours per response 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <b>CLACKSON TIMOTHY P</b>			2. Issuer Name and Ticker or Trading Symbol <b>ARIAD PHARMACEUTICALS INC</b> [ARIA]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>President, R&amp;D, CSO</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>01/15/2013</b>			6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person		
C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET			4. If Amendment, Date Original Filed(Month/Day/Year)					
(Street) CAMBRIDGE, MA 02139								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)				Price
Common Stock	01/15/2013		M		4,766 <sup>(1)</sup>	A	\$5.23	288,037	D	
Common Stock	01/15/2013		M		44,542 <sup>(2)</sup>	A	\$4.49	332,579	D	
Common Stock	01/15/2013		M		8,631 <sup>(3)</sup>	A	\$7.82	341,210	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$5.23	01/15/2013		M		4,766		09/09/2006	09/09/2014	Common Stock	4,766	\$ 0	0	D	
Employee Stock	\$4.49	01/15/2013		M		44,542		04/16/2008	04/16/2017	Common Stock	44,542	\$ 0	0	D	

Option (Right to Buy)															
Employee Stock Option (Right to Buy)	\$7.82	01/15/2013		<u>M</u>		8,631	04/01/2012	04/01/2021	Common Stock	8,631	\$ 0	17,262	D		

**Explanation of Responses:**

1. Shares were acquired upon the exercise of outstanding stock options at \$5.23 per share.
2. Shares were acquired upon the exercise of outstanding stock options at \$4.49 per share.
3. Shares were acquired upon the exercise of outstanding stock options at \$7.82 per share.

**Signatures**

/s/Edward M. Fitzgerald, Attorney-in-Fact

\*\* Signature of Reporting Person

01/17/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**